Regeneron said total revenues for Q1 2024 decreased 1% from $3,162 million a year earlier to $3,145 million. Excluding Ronapreve, total revenues rose 7% to $3,145 million from $2,940 million.

1. 01

   Regeneron said total revenues for Q1 2024 decreased 1% from $3,162 million a year earlier to $3,145 million. Excluding Ronapreve, total revenues rose 7% to $3,145 million from $2,940 million.

2. 02

   The company said U.S. net sales of EYLEA HD and EYLEA fell 2% year over year to $1,402 million in Q1 2024. Of that total, EYLEA HD accounted for $200 million, while EYLEA alone fell 16% to $1,202 million.

3. 03

   Regeneron said GAAP net income for Q1 2024 fell 12% to $722 million from $818 million a year earlier. GAAP diluted earnings per share were $6.27, and non-GAAP diluted earnings per share were $9.55.

4. 04

   The company said its board approved an additional share repurchase program of up to $3.0 billion in April 2024, with no time limit. It said it repurchased shares for $298 million in Q1 2024, and that as of March 31, $1.2 billion remained available under the existing program.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.